Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Oxsoralen-Ultra, 8-MOP, Meladinine, UVADEX
Methoxsalen is a photosensitizing medication used in combination with ultraviolet A (UVA) light therapy (PUVA) to treat severe psoriasis, cutaneous T-cell lymphoma (CTCL), and vitiligo. It belongs to the class of drugs known as psoralens. Methoxsalen works by enhancing the skin's sensitivity to UVA light, which helps slow the growth of affected skin cells. It's administered orally or topically.
Used with UVA light to treat severe psoriasis, cutaneous T-cell lymphoma, and vitiligo.
May increase the risk of skin cancer with long-term use. Patients should be carefully monitored for signs of skin malignancy.
Outcome:
Increased risk of severe sunburn and photosensitivity reactions.
Mechanism:
Additive photosensitizing effects.
Outcome:
May decrease the effectiveness of methoxsalen.
Mechanism:
Unknown.
Outcome:
May reduce absorption of methoxsalen.
Mechanism:
Changes in stomach pH.
Most likely new formulation: Nano-encapsulated methoxsalen for targeted delivery (Year 2026, 70% confidence)
Based on current usage trends and clinical trial activity, there is a 20% likelihood of a new topical formulation being approved within the next 5 years.
Photosensitizing Agent, Psoralen
Furocoumarin